IRVINE, Calif., May 16 /PRNewswire-FirstCall/ -- IDM Pharma, Inc.
(Nasdaq: IDMI) today announced that clinical data presentations evaluating
the Company's lead product candidates will be made at the upcoming 44th
American Society of Clinical Oncology (ASCO) annual meeting. Data presented
at the meeting will support improved survival for patients with metastatic
osteosarcoma treated with L-MTP-PE, as well as patients with non-small lung
cancer treated with IDM-2101.
Presentation highlights are as follows:
"Addition of Muramyl Tripeptide to Chemotherapy for Patients with Newly
Diagnosed Metastatic Osteosarcoma: a Report from the Children's Oncology
Presenter: Alexander J Chou, MD, Department of Pediatrics, Memorial
Sloan-Kettering Cancer Center
Date/Time: Poster presentation, Sunday, June 1, 2008, 2 - 6 p.m., S Hall
A1; poster discussion period, 4:45 - 6 p.m., S504
Abstract Number: 10018
Poster Number: 52B
"Induction of immune responses and clinical activity in a Phase 2 trial of
IDM-2101, a 10-epitope CTL vaccine, in metastatic NSCLC patients"
Presenter: Minal Barve, MD, practice director, Mary Crowley Cancer
Date/Time: Sunday, June 1, 2008, 2 - 6 p.m., S Hall A1
Abstract Number: 8057
Poster Number: 43D
The 2008 ASCO annual meeting abstracts are currently available at http://www.asco.org.
About IDM Pharma
IDM Pharma is focused on the development of innovative cancer products
that either destroy cancer cells by activating the immune system or prevent
tumor recurrence by triggering a specific adaptive immune r
|SOURCE IDM Pharma, Inc.|
Copyright©2008 PR Newswire.
All rights reserved